Dose response for T-cell receptor (TCR) mutants in patients repeatedly treated with 131I for thyroid cancer.
The T-cell receptor mutant frequency (TCR-Mf) was measured in 53 young adults, who were treated with radioiodine for thyroid cancer. Patients came from the southern part of Belarus. This region had suffered the most from the Chernobyl Disaster. TCR-Mf was determined by flow cytometry before and after 1 to maximal 10 treatments. Before treatment, TCR-Mf of patients was 2.0 x 10(-14). This Mf value is in the same range as that of young healthy students. After radioiodine therapy (RIT), TCR-Mf increases within about half a year to a maximum. The increase per one mGy to red marrow was 8.7 x 10(-7). After the maximum TCR-Mf declines exponentially. The half-life of TCR mutants was found to be 3.2 years. On the basis of these data, a calibration curve for the use of TCR-Mf as a biological dosimeter is given.
Vershenya
Stanislav
S
Klinik und Poliklinik für Nuklearmedizin der Universität, Würzburg, Josef-Schneider-Street 2, D-97080 Wuerzburg, Germany.
Biko
Johannes
J
Drozd
Valentina
V
Lorenz
Reinhard
R
Reiners
Christoph
C
Hempel
Klaus
K
D000293:Adolescent; D000328:Adult; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D009154:Mutation / Q000235:genetics*; D009367:Neoplasm Staging; D009381:Neoplasms, Radiation-Induced / Q000532:radiotherapy*; D018788:Radioactive Hazard Release; D011948:Receptors, Antigen, T-Cell / Q000235:genetics* / Q000528:radiation effects; D013964:Thyroid Neoplasms / Q000532:radiotherapy*; D013997:Time Factors
D007457:Iodine Radioisotopes; D011948:Receptors, Antigen, T-Cell